| Browse All

MapLight Therapeutics, Inc. (MPLT)

Healthcare | Biotechnology | Redwood City, United States | NasdaqGS
30.05 USD +1.54 (5.402%) ⇧ (April 17, 2026, 4 p.m. EDT)
After hours: 30.05

Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 11, 2026, 1:26 p.m. EDT

MPLT is a biotechnology stock with a recent price surge, but fundamentals show negative earnings and poor profitability. The stock has a strong short-term momentum with a recent 52-week high, but the price-to-book ratio and negative earnings suggest caution. The lack of dividends and high debt-to-equity ratio make it unsuitable for dividend-focused investors. The forecasting model indicates low price direction predictability, suggesting short-term volatility. Long-term investors should consider the company's financial health and potential for future growth, but the current conditions do not support a strong buy recommendation.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoETS ✓0.111464
AutoARIMA0.112898
MSTL0.113387
AutoTheta0.113887

Forecast horizon: 45 days | Selected: AutoETS

Forecast Reliability
Score 24%
H-stat 6.93
Ljung-Box p 0.000
Jarque-Bera p 0.000
Excess Kurtosis 0.92
Attribute Value
Sector Healthcare
Debt to Equity Ratio 1.266
Market Cap 1,363,459,584
Forward P/E -8.04
Website https://www.maplightrx.com

Info Dump

Attribute Value
52 Week Change 0.5545256
Address1 800 Chesapeake Drive
All Time High 31.13
All Time Low 12.24
Ask 30.42
Ask Size 2
Average Analyst Rating 1.3 - Strong Buy
Average Daily Volume10 Day 291,430
Average Daily Volume3 Month 215,391
Average Volume 215,391
Average Volume10Days 291,430
Bid 29.89
Bid Size 2
Book Value 10.412
City Redwood City
Compensation As Of Epoch Date 1,735,603,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 30.05
Current Ratio 20.006
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 31.13
Day Low 29.2
Debt To Equity 1.266
Display Name MapLight Therapeutics
Earnings Timestamp 1,774,528,200
Earnings Timestamp End 1,778,761,800
Earnings Timestamp Start 1,778,761,800
Ebitda -168,504,992
Ebitda Margins 0.0
Enterprise To Ebitda -6.075
Enterprise Value 1,023,622,848
Eps Current Year -4.61333
Eps Forward -3.73667
Eps Trailing Twelve Months -18.56
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 19.5585
Fifty Day Average Change 10.491499
Fifty Day Average Change Percent 0.53641635
Fifty Two Week Change Percent 55.45256
Fifty Two Week High 31.13
Fifty Two Week High Change -1.0799999
Fifty Two Week High Change Percent -0.03469322
Fifty Two Week Low 12.24
Fifty Two Week Low Change 17.81
Fifty Two Week Low Change Percent 1.4550654
Fifty Two Week Range 12.24 - 31.13
Financial Currency USD
First Trade Date Milliseconds 1,761,571,800,000
Float Shares 12,740,571
Forward Eps -3.73667
Forward P E -8.04192
Free Cashflow -83,129,872
Full Exchange Name NasdaqGS
Full Time Employees 133
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.52266
Held Percent Institutions 0.52513003
Implied Shares Outstanding 45,373,033
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,025-10-27
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.
Long Name MapLight Therapeutics, Inc.
Market us_market
Market Cap 1,363,459,584
Market State CLOSED
Max Age 86,400
Message Board Id finmb_605975835
Most Recent Quarter 1,767,139,200
Net Income To Common -161,152,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 1,274,787,233
Number Of Analyst Opinions 6
Open 29.24
Operating Cashflow -138,136,992
Operating Margins 0.0
Payout Ratio 0.0
Phone 617 984 6300
Post Market Change 0.0
Post Market Change Percent 0.0
Post Market Price 30.05
Post Market Time 1,776,463,443
Previous Close 28.51
Price Eps Current Year -6.513733
Price Hint 2
Price To Book 2.886093
Profit Margins 0.0
Quick Ratio 18.8
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.28571
Region US
Regular Market Change 1.54
Regular Market Change Percent 5.40161
Regular Market Day High 31.13
Regular Market Day Low 29.2
Regular Market Day Range 29.2 - 31.13
Regular Market Open 29.24
Regular Market Previous Close 28.51
Regular Market Price 30.05
Regular Market Time 1,776,456,000
Regular Market Volume 227,694
Return On Assets -0.34287
Return On Equity -0.56193
Sand P52 Week Change 0.36506534
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 42,436,326
Shares Percent Shares Out 0.0334
Shares Short 1,418,306
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 1,355,099
Short Name MapLight Therapeutics, Inc.
Short Percent Of Float 0.034
Short Ratio 6.22
Source Interval 15
State CA
Symbol MPLT
Target High Price 37.0
Target Low Price 28.0
Target Mean Price 32.66667
Target Median Price 33.0
Total Cash 305,103,008
Total Cash Per Share 6.93
Total Debt 5,802,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -18.56
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 18.132753
Two Hundred Day Average Change 11.917246
Two Hundred Day Average Change Percent 0.6572221
Type Disp Equity
Volume 227,694
Website https://www.maplightrx.com
Zip 94,063